Vera Therapeutics, Inc. (VERA)

Market Cap	2.70B
Revenue (ttm)	n/a
Net Income (ttm)	-134.38M
Shares Out	63.32M
EPS (ttm)	-2.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,006,301
Open	41.66
Previous Close	42.05
Day's Range	40.96 - 45.06
52-Week Range	14.20 - 51.61
Beta	1.08
Analysts	Strong Buy
Price Target	59.22 (+39.01%)
Earnings Date	Nov 7, 2024

About VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was for...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 14, 2021
• Employees: 51
• Stock Exchange: NASDAQ
• Ticker Symbol: VERA
• Website: https://veratx.com

Analyst Forecast

According to 9 analysts, the average rating for VERA stock is "Strong Buy." The 12-month stock price forecast is $59.22, which is an increase of 39.01% from the latest price.

Price Target

$59.22

(39.01% upside)

Analyst Consensus: Strong Buy